Short answer
Labcorp (LH) filed an 8-K current report with the SEC on August 14, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Megan D. Bailey resigning as EVP and President, Central Laboratories and International, effective September 4, 2026.
Labcorp 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Megan D. Bailey resigning as EVP and President, Central Laboratories and International, effective September 4, 2026
- Brian J. Caveney assuming EVP and President, Biopharma Laboratory Services, effective September 1, 2026
- Caveney retaining Chief Medical and Scientific Officer role and adding Central Laboratories oversight
- Leadership transition creates near-term execution risk across Central Laboratories and International operations
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Labcorp 8-K filings
Get the next LH 8-K as it lands
Follow LH for push alerts, or ask the research agent what this filing means.